A prospective observational study on remimazolam use and patient satisfaction in real-world clinical practice

A prospective observational study on remimazolam use and patient satisfaction in real-world clinical practice - Daily clinical practice of remimazolam (DOREMI) study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059792

Enrollment

Registered

2025-11-16

Start date

2025-11-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing upper gastrointestinal endoscopy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients scheduled to undergo upper gastrointestinal endoscopy using remimazolam at the study institution for screening, surveillance, or diagnostic purposes between the date of UMIN registration publication and March 2028. 2. Patients who agree to participate in the study and are 18 years of age or older at the time of obtaining informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with ASA physical status classification IV or higher 2. Patients with acute angle-closure glaucoma 3. Patients with myasthenia gravis 4. Patients with a history of allergy to any component of remimazolam

Design outcomes

Primary

Measure	Time frame
Recovery room stay (time until the Modified Aldrete Score reaches 9)	—

Countries

Japan

Contacts

Public ContactNatsumi Maeda

Osaka Metropolitan University Department of Gastroenterology

natsu-0724@omu.ac.jp0666453811

Outcome results